Pharmacogenomics Technology Market Size, Share & Trends Report

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report By Therapeutic Area (Oncology Neurological, Cardiovascular, Immunology Disorders), By Technology, And Segment Forecasts, 2018 - 2025

  • Published Date: Jun 2017
  • Report ID: GVR-1-68038-940-1
  • Number of Pages: 150
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2016

Table of Contents

Chapter 1 Research Methodology
                1.1 Region Wise Market Calculation
                    1.1.1 Region Wise Market: Base Estimates
                    1.1.2 Global Market: CAGR Calculation
                1.2 Region based segment share calculation
                1.3 Data Analysis
                1.4 List of Primary & Secondary Sources
Chapter 2 Executive Summary
                2.1 Market Snapshot
Chapter 3 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market Variables, Trends& Scope
                3.1 Companion Diagnostics: Categorization
                    3.1.1 Screening and detection
                    3.1.2 Prognosis
                    3.1.3 Theranostics
                    3.1.4 Monitoring
                    3.1.5 Recurrence
                3.2 Market Segmentation & Scope
                    3.2.1 Market Driver Analysis
                        3.2.1.1 Rising adoption of companion diagnostics
                        3.2.1.2 Accelerating demand for targeted cancer treatment & tailored drugs
                            3.2.1.2.1 Cancer incidence rate,2016
                        3.2.1.3 Technological advancements pertaining to sequencing
                        3.2.1.4 Collaborations between diagnostic and pharma entities
                            3.2.1.4.1 Business models that benefit CDx developers in early partnering deals
                        3.2.1.5 Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
                    3.2.2 Market Restraint Analysis
                        3.2.2.1 Challenges associated with reimbursement
                        3.2.2.2 Robustness of the financing environment for diagnostic and research tools companies
                        3.2.2.3 Laboratory developed tests anticipated to reduce adoption of CDx
                3.3 Penetration & Growth Prospect Mapping for Therapeutic Area, 2016
                3.4 Development of NGS based Companion Diagnostics
                    3.4.1 Associated operational challenges
                        3.4.1.1 Assay turnaround time
                        3.4.1.2 Sample quantity
                        3.4.1.3 Unavailability of CROs with CLIA NGS capabilities
                    3.4.2 Technical and analytical challenges for NGS assays in the clinic
                        3.4.2.1 Design & QC standardization
                        3.4.2.2 Post analytical challenges
                        3.4.2.3 Unavailability of CROs with CLIA NGS capabilities
                    3.4.3 Strategic challenges for drug and diagnostic developers
                3.5 Companion Diagnostics Reimbursement Environment
                    3.5.1 Issues in technology assessment and payer decision making
                    3.5.2 Potential risks and benefits of pharmacogenomics from the payer perspective
                3.6 Companion Diagnostics Regulatory Environment
                    3.6.1 Companion diagnostics regulatory environment, U.S.
                    3.6.2 Companion diagnostics regulatory environment, Europe
                    3.6.3 Companion diagnostics regulatory environment, Asia Pacific
                3.7 Companion Diagnostics Regulatory Issues & Recall
                    3.7.1 Dako FDA warning letter
                    3.7.2 HercepTest recall
                    3.7.3 Cobas KRAS test recall
                    3.7.4 Cobas BRF V600E test recall
                    3.7.5 Leica Bond HER2 IHC system
                3.8 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) - SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
                3.9 Industry Analysis - Porter’s
Chapter 4 Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis
                4.1 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market: Therapeutic Area Movement Analysis
                4.2 Oncology
                    4.2.1 Global oncology market, 2014 - 2025 (USD Million)
                    4.2.2 Lung cancer
                        4.2.2.1 Global lung cancer market, 2014 - 2025 (USD Million)
                    4.2.3 Breast cancer
                        4.2.3.1 Global breast cancer market, 2014 - 2025 (USD Million)
                    4.2.4 Colorectal cancer
                        4.2.4.1 Global colorectal cancer market, 2014 - 2025 (USD Million)
                    4.2.5 Cervical cancer
                        4.2.5.1 Global cervical cancer market, 2014 - 2025 (USD Million)
                    4.2.6 Other cancers
                        4.2.6.1 Global other cancers market, 2014 - 2025 (USD Million)
                4.3 Neurology
                    4.3.1 Global neurology market, 2014 - 2025 (USD Million)
                4.4 Cardiovascular Diseases
                    4.4.1 Global cardiovascular diseases market, 2014 - 2025 (USD Million)
                4.5 Immunological Disorders
                    4.5.1 Global immunological disorders market, 2014 - 2025 (USD Million)
                4.6 Other Disorders
                    4.6.1 Global other disorders market, 2014 - 2025 (USD Million)
Chapter 5 Pharmacogenomics Technology: Technology Estimates & Trend Analysis
                5.1 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market: Technology Movement Analysis
                5.2 Polymerase Chain Reaction(PCR)
                    5.2.1 Global polymerase chain reaction market, 2014 - 2025 (USD Million)
                5.3 In-situ Hybridization
                    5.3.1 Global in-situ hybridization market, 2014 - 2025 (USD Million)
                5.4 Immunohistochemistry
                    5.4.1 Global immunohistochemistry market, 2014 - 2025 (USD Million)
                5.5 Sequencing
                    5.5.1 Global sequencing market, 2014 - 2025 (USD Million)
                5.6 Other Technologies
                    5.6.1 Global other technologies market, 2014 - 2025 (USD Million)
Chapter 6 Pharmacogenomics Technology: Regional Estimates & Trend Analysis, by Therapeutic Area & Application
                6.1 Pharmacogenomics Technology (Theranostics and Companion Diagnostics) Market Share by Region, 2016 & 2025
                6.2 North America
                    6.2.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                    6.2.2 Market, by technology, 2014 - 2025 (USD Million)
                    6.2.3 U.S.
                        6.2.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                        6.2.3.2 Market, by technology, 2014 - 2025 (USD Million)
                    6.2.4 Canada
                        6.2.4.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                        6.2.4.2 Market, by technology 2014 - 2025 (USD Million)
                6.3 Europe
                    6.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                    6.3.2 Market, by technology, 2014 - 2025 (USD Million)
                    6.3.3 Germany
                        6.3.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                        6.3.3.2 Market, by technology, 2014 - 2025 (USD Million)
                    6.3.4 U.K.
                        6.3.4.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                        6.3.4.2 Market, by technology, 2014 - 2025 (USD Million)
                6.4 Asia Pacific
                    6.4.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                    6.4.2 Market, by technology, 2014 - 2025 (USD Million)
                    6.4.3 Japan
                        6.4.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                        6.4.3.2 Market, by technology, 2014 - 2025 (USD Million)
                    6.4.4 China
                        6.4.4.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                        6.4.4.2 Market, by technology, 2014 - 2025 (USD Million)
                6.5 Latin America
                    6.5.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                    6.5.2 Market, by technology, 2014 - 2025 (USD Million)
                    6.5.3 Brazil
                        6.5.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                        6.5.3.2 Market, by technology, 2014 - 2025 (USD Million)
                6.6 MEA
                    6.6.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                    6.6.2 Market, by technology, 2014 - 2025 (USD Million)
                    6.6.3 South Africa
                        6.6.3.1 Market, by therapeutic area, 2014 - 2025 (USD Million)
                        6.6.3.2 Market, by technology, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
                7.1 Strategy framework
                7.2 Market participation categorization
                7.3 Company Profiles
                    7.3.1 Illumina Inc.
                        7.3.1.1 Company Overview
                        7.3.1.2 Financial Performance
                        7.3.1.3 Product Benchmarking
                        7.3.1.4 Strategic Initiatives
                    7.3.2 F Hoffman La Roche
                        7.3.2.1 Company Overview
                        7.3.2.2 Financial Performance
                        7.3.2.3 Product Benchmarking
                        7.3.2.4 Strategic Initiatives
                    7.3.3 Qiagen NV
                        7.3.3.1 Company Overview
                        7.3.3.2 Financial Performance
                        7.3.3.3 Product Benchmarking
                        7.3.3.4 Strategic Initiatives
                    7.3.4 Myriad Genetics Inc.
                        7.3.4.1 Company Overview
                        7.3.4.2 Financial Performance
                        7.3.4.3 Product Benchmarking
                        7.3.4.4 Strategic Initiatives
                    7.3.5 Agilent Technologies
                        7.3.5.1 Company Overview
                        7.3.5.2 Financial Performance
                        7.3.5.3 Product Benchmarking
                        7.3.5.4 Strategic Initiatives
                    7.3.6 Foundation Medicine, Inc
                        7.3.6.1 Company Overview
                        7.3.6.2 Financial Performance
                        7.3.6.3 Product Benchmarking
                        7.3.6.4 Strategic Initiatives
                    7.3.7 Leica Biosystems Nussloch GmBH
                        7.3.7.1 Company Overview
                        7.3.7.2 Financial Performance
                        7.3.7.3 Product Benchmarking
                        7.3.7.4 Strategic Initiatives
                    7.3.8 Merck & Co Inc
                        7.3.8.1 Company Overview
                        7.3.8.2 Financial Performance
                        7.3.8.3 Product Benchmarking
                        7.3.8.4 Strategic Initiatives
                    7.3.9 Oxford Cancer Biomarkers Ltd.
                        7.3.9.1 Company Overview
                        7.3.9.2 Financial Performance
                        7.3.9.3 Product Benchmarking
                        7.3.9.4 Strategic Initiatives
                    7.3.10 Astra Zeneca
                        7.3.10.1 Company Overview
                        7.3.10.2 Financial Performance
                        7.3.10.3 Product Benchmarking
                        7.3.10.4 Strategic Initiatives
                    7.3.11 Thermo Fisher Scientific, Inc.
                        7.3.11.1 Company Overview
                        7.3.11.2 Financial Performance
                        7.3.11.3 Product Benchmarking
                        7.3.11.4 Strategic Initiatives
                    7.3.12 Beckman Coulter Inc.
                        7.3.12.1 Company Overview
                        7.3.12.2 Financial Performance
                        7.3.12.3 Product Benchmarking
                        7.3.12.4 Strategic Initiatives
                    7.3.13 Abbott Laboratories
                        7.3.13.1 Company Overview
                        7.3.13.2 Financial Performance
                        7.3.13.3 Product Benchmarking
                        7.3.13.4 Strategic Initiatives
                    7.3.14 Pfizer
                        7.3.14.1 Company Overview
                        7.3.14.2 Financial Performance
                        7.3.14.3 Product Benchmarking
                        7.3.14.4 Strategic Initiatives
                    7.3.15 Focus Diagnostics
                        7.3.15.1 Company Overview
                        7.3.15.2 Financial Performance
                        7.3.15.3 Product Benchmarking
                        7.3.15.4 Strategic Initiatives
                    7.3.16 AmeriPath Inc
                        7.3.16.1 Company Overview
                        7.3.16.2 Financial Performance
                        7.3.16.3 Product Benchmarking
                        7.3.16.4 Strategic Initiatives
                    7.3.17 Bristol Myers Squibb
                        7.3.17.1 Company Overview
                        7.3.17.2 Financial Performance
                        7.3.17.3 Product Benchmarking
                        7.3.17.4 Strategic Initiatives
                    7.3.18 Novartis Ag
                        7.3.18.1 Company Overview
                        7.3.18.2 Financial Performance
                        7.3.18.3 Product Benchmarking
                        7.3.18.4 Strategic Initiatives


List of Tables

TABLE 1 Healthcare expenditure levels, 2015
TABLE 2 North America pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 3 North America oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 4 North America pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 5 U.S. pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 6 U.S. oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 7 U.S. pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 8 Canada pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 9 Canada oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 10 Canada pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 11 Europe pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 12 Europe oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 13 Europe pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 14 Germany pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 15 Germany oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 16 Germany pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 17 U.K. pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 18 U.K. oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 19 UK pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 20 Asia Pacific pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 21 Asia Pacific oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 22 Asia Pacific pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 23 Japan pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 24 Japan oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 25 Japan pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 26 China pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 27 China oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 28 China pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 29 Latin America pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 30 Latin America oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 31 Latin America pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 32 Brazil pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 33 Brazil oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 34 Brazil pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 35 MEA pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 36 MEA oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 37 MEA pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)
TABLE 38 South Africa pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by therapeutic area, 2014 - 2025 (USD Million)
TABLE 39 South Africa oncology pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by application, 2014 - 2025 (USD Million)
TABLE 40 South Africa pharmacogenomics technology (theranostics and companion diagnostics) market estimates & forecasts, by technology, 2014 - 2025 (USD Million)


List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Cost per raw megabase (Mb) of DNA sequence (USD)
FIG. 12 Cost per genome
FIG. 13 Necessary alliances for the development of successful companion diagnostics
FIG. 14 Expected rise in expenditure for cancer treatment (USD Million)
FIG. 15 Market restraint relevance analysis (Current & future impact)
FIG. 16 Penetration & growth prospect mapping for therapeutic area, 2016
FIG. 17 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 18 Porter’s Five Forces Analysis
FIG. 19 Companion diagnostics & pharmacogenomics market: Therapeutic area outlook key takeaways
FIG. 20 Companion diagnostics & pharmacogenomics market: Application movement analysis
FIG. 21 Global oncology market, 2014 - 2025 (USD Million)
FIG. 22 Global lung cancer market, 2014 - 2025 (USD Million)
FIG. 23 Global breast cancer market, 2014 - 2025 (USD Million)
FIG. 24 Global colorectal cancer market, 2014 - 2025 (USD Million)
FIG. 25 Global cervical cancer market, 2014 - 2025 (USD Million)
FIG. 26 Global other cancers market, 2014 - 2025 (USD Million)
FIG. 27 Global neurology market, 2014 - 2025 (USD Million)
FIG. 28 Global cardiovascular diseases market, 2014 - 2025 (USD Million)
FIG. 29 Global immunological disorders market, 2014 - 2025 (USD Million)
FIG. 30 Global other disorders market, 2014 - 2025 (USD Million)
FIG. 31 Companion diagnostics & pharmacogenomics market: Technology outlook key takeaways
FIG. 32 Global pharmacogenomics technology (theranostics and companion diagnostics) market: Technology movement analysis
FIG. 33 Global polymerase chain reaction market, 2014 - 2025 (USD Million)
FIG. 34 Global in-situ hybridization market, 2014 - 2025 (USD Million)
FIG. 35 Global immunohistochemistry market, 2014 - 2025 (USD Million)
FIG. 36 Global sequencing market, 2014 - 2025 (USD Million)
FIG. 37 Global other technologies market, 2014 - 2025 (USD Million)
FIG. 38 Regional market place: Key takeaway
FIG. 39 Companion diagnostics & pharmacogenomics regional outlook, 2016 & 2025
FIG. 40 North America pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 41 U.S. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 42 Canada. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 43 Europe pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 44 Germany. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 45 U.K. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 46 Asia Pacific pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 47 Japan. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 48 China. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 49 Latin America. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 50 Brazil. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 51 Middle East & Africa. pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 52 South Africa pharmacogenomics technology (theranostics and companion diagnostics) market, 2014 - 2025 (USD Million)
FIG. 53 Strategy framework
FIG. 54 Participant categorization

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.